Drug Profile
YHB 1411-2
Alternative Names: YHB 14112Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in South Korea (IV, Infusion)
- 15 Dec 2014 Phase-I development is ongoing in South Korea
- 01 Nov 2013 Yuhan completes a phase I trial in Rheumatoid arthritis (in volunteers) in South Korea (NCT01525147)